Whole-exome sequencing uncovers frequent GNAS mutations in
      intraductal papillary mucinous neoplasms of the pancreas by Furukawa, Toru et al.
Whole-exome sequencing uncovers
frequent GNAS mutations in intraductal
papillary mucinous neoplasms of the
pancreas
Toru Furukawa
1,2,4, Yuko Kuboki
1,2, Etsuko Tanji
1, Shoko Yoshida
1, Takashi Hatori
2,
Masakazu Yamamoto
2, Noriyuki Shibata
3,4, Kyoko Shimizu
2, Naoyuki Kamatani
1 & Keiko Shiratori
2
1Institute for Integrated Medical Sciences,
2Institute of Gastroenterology,
3Department of Pathology,
4Department of Surgical
Pathology, Tokyo Women’s Medical University, Tokyo, Japan.
Intraductal papillary mucinous neoplasm (IPMN) is a common pancreatic cystic neoplasm that is often
invasive and metastatic, resulting in a poor prognosis. Few molecular alterations unique to IPMN are
known. We performed whole-exome sequencing for a primary IPMN tissue, which uncovered somatic
mutationsinKCNF1,DYNC1H1,PGCP,STAB1,PTPRM,PRPF8,RNASE3,SPHKAP,MLXIPL,VPS13C,
PRCC, GNAS, KRAS, RBM10, RNF43, DOCK2, and CENPF. We further analyzed GNAS mutations in
archival cases of 118 IPMNs and 32 pancreatic ductal adenocarcinomas (PDAs), which revealed that 48
(40.7%) of the 118 IPMNs but none of the 32 PDAs harbored GNAS mutations. G-protein alpha-subunit
encoded by GNAS and its downstream targets, phosphorylated substrates of protein kinase A, were
evidently expressed in IPMN; the latter was associated with neoplastic grade. These results indicate that
GNASmutationsarecommonandspecificforIPMN,andactivationofG-proteinsignalingappearstoplaya
pivotal role in IPMN.
I
ntraductal papillary mucinous neoplasm of the pancreas (IPMN) is a cystic neoplasm consisting of dilated
ducts lined by neoplastic cells that secrete copious mucin
1–3. This neoplasm is distinct from pancreatic ductal
adenocarcinoma (PDA), a conventional type of pancreatic cancer that usually forms a solid and ill-defined
mass. Although IPMN is less frequent than PDA, it is fairly common; in the US, the incidence is reported to be
2.04 per 100000 person-years in the general population, and in Japan, IPMN is prevalent in 5% of all registered
surgical cases of pancreatic neoplasms with available histological data
4,5. Patients with IPMN suffer from acute
pancreatitis due to obstruction of the ducts with mucus or pancreatic functional insufficiency resulting from
chronicatrophyoftheparenchyma
6.Moreover,IPMNsareoftenassociatedwithinvasivecarcinoma,whichleads
to a poor outcome. The prognosis of patients with IPMN with an associated invasive carcinoma is a 5-year
survivalrateof27%–60%,dependingupontheextentandhistologicaltypeoftheinvasivecomponent
7.Although
thesedistinctanduniquefeaturesarewell-known,molecularalterationsspecifictoIPMNarepoorlyunderstood.
A better understanding of the molecular alterations specific to IPMN may lead to development of more efficient
methods of prevention, early diagnosis, and cure of this disease.
In this study, we carried out whole-exome sequencing using DNA obtained from primary IPMN tissue and
foundanumberofpreviouslyunidentifiedmutatedgenes.Amongthem,wethenfocusedonmutationsinGNAS,
a gene encoding the guanine nucleotide-binding protein (G-protein) alpha subunit (Gsa), in archival cases of
IPMN and found that the gene was frequently mutated in IPMN. We further studied the clinicopathological
relevance of associated molecules of these mutations in G-protein signaling in this neoplasm.
Results
Whole-exomesequencingofIPMN.Whole-exomesequencingwascarriedoutonDNAextractedfromprimary
IPMN tissue, using the solution hybridization-based exon-enrichment method and a massively parallel deep
sequencer. The analyzed tumor was an intestinal-type high-grade IPMN with minimal invasion from a 76-year-
old Japanese man. Tumor cells and non-tumor cells were separately collected from a frozen sample of primary
tissue by laser-capture microdissection. Raw sequence data revealed 68830 single nucleotide polymorphisms
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SCIENTIFIC REPORTS | 1 : 161 | DOI: 10.1038/srep00161 1(SNPs) and 4139 small insertions and deletions (InDls) in the tumor
cells. A series of subsequent qualifications of these data narrowed
down these variations into 21 nonsynonymous tumor-specific
SNPs and 6 InDls (Fig. 1). We validated these SNPs and InDls by
the Sanger method and confirmed that 13 SNPs and 4 InDls were
somatic mutations. These confirmed mutated genes were KCNF1,
DYNC1H1, PGCP, STAB1, PTPRM, PRPF8, RNASE3, SPHKAP,
MLXIPL, VPS13C, PRCC, GNAS, KRAS, RBM10, RNF43, DOCK2,
and CENPF (Table 1). Among these mutated genes, we focused on
GNASthatisknowntobemutatedinhumantumors,mainlyinthose
of endocrine origin and rarely in other common cancers, including
pancreatic cancer.
GNAS mutations in archival cases of IPMN and PDA. We further
examined mutations in GNAS in 118 archival cases of IPMN and,
for comparison, 32 cases of PDA. Somatic mutations in GNAS were
Figure 1 | Processing of data obtained by whole-exome sequencing using a massively parallel deep sequencer.
Table 1 | Mutations identified in IPMN by whole-exome sequencing
Gene Accession No. Mutation Protein Function*
KCNF1 NM_002236 c.802G.A p.V268M potassium channel activity
DYNC1H1 NM_001376 c.9739C.T p.Q3247X ATP binding
PGCP NM_016134 c.1388C.T p.A463V metal ion binding
STAB1 NM_015136 c.1504G.A p.A514T receptor activity
PTPRM NM_001105244 c.1312G.A p.E438K protein tyrosine phosphatase
activity
PRPF8 NM_006445 c.5525C.T p.A1842V RNA binding
RNASE3 NM_002935 c.164G.A p.R55Q ribonuclease activity
SPHKAP NM_001142644 c.3710C.T p.S1237L protein binding
MLXIPL NM_032954 c.2056C.T p.R686C transcription activator activity
VPS13C NM_017684 c.5992A.G p.I1998V protein localization
PRCC NM_005973 c.958C.T p.P320S protein binding
GNAS NM_000516 c.602G.A p.R201H G-protein beta/gamma-subunit
complex binding
KRAS NM_033360 c.35G.A p.G12D GDP binding
RBM10 NM_005676 c.1817-1818insA p.E606EfsX37 RNA binding
RNF43 NM_017763 c.931-932insC p.L311PfsX132 Ubiquitin ligase activity
DOCK2 NM_004946 c.3695-3700delTGGACT p.L1232-C1234delinsR GTP binding
CENPF NM_016343 c.327_328insA p.Q110TfsX10 chromatin binding
*Gene Ontology (http://www.ebi.ac.uk/GOA/).
G-protein, the guanine nucleotide-binding protein; IPMN, intraductal papillary mucinous neoplasm.
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the 118 cases. All of these mutations involved codon 201 of GNAS,
where arginine was substituted by cysteine or histidine (R201C or
R201H) (Supplementary Table S1 online). However, the GNAS
mutation was not observed in any of the examined cases of PDAs.
This association between GNAS mutations and pathological types of
tumors was statistically significant (p 5 6.58 3 10
27; Fisher’s exact
test)(Table2).WealsoexaminedsomaticmutationsinKRAS,agene
known to be commonly mutated in PDAs and IPMNs. Mutations in
KRAS were observed in 56 (48%) of the 118 IPMNs and in 25 (78%)
of the 32 PDAs. The KRAS mutations were significantly more
frequent in PDAs than in IPMNs (p 5 0.0016 by Fisher’s exact
test) (Table 2 and Supplementary Table S1 online). In addition,
we examined 25 cultured pancreatic cancer cell lines and found
that none of them harbored the GNAS mutation, whereas most of
them, i.e., 24 of the 25, harbored KRAS mutations (Supplementary
Table S1 online). These results indicate that GNAS mutations are
frequent and highlyspecific for IPMN among pancreatic neoplasms.
Moreover, 30 (25%) of the 118 IPMNs harbored concurrent muta-
tions in GNAS and KRAS, indicating a significant co-occurrence of
these mutations in IPMNs (p 5 0.0057; Fisher’s exact test).
G-protein signaling in IPMN and PDA. To identify the biological
significance of GNAS in pancreatic neoplasms, we performed im-
munohistochemical analysis and examined the expression of Gsa
in IPMNs and PDAs. We found that Gsa was more frequently and
abundantly expressed in IPMNs than in PDAs, i.e., 117 (99%) of the
118 IPMNs and 19 (59%) of the 32 PDAs showed moderate or high
expression (p , 0.001; ANOVA; Fig. 2, Table 2 and Supplementary
Table S1 online). GNAS mutations were not significantly associated
with Gsa expression inIPMNs (p 50.061 byANOVA). Phosphory-
lated substrates of cyclic-AMP (cAMP)-dependent protein kinase/
protein kinase A (PKA), a downstream target of Gsa in the G-
protein-coupled receptor (GPCR)-cAMP signaling pathway
8, were
observed in both IPMNs and PDAs, i.e., 92 (78%) of the 118 IPMNs
and 23 (72%) of the 32 PDAs showed moderate or high expression
(p 5 0.425; ANOVA; Fig. 2, Table 2 and Supplementary Table S1
online). In IPMNs, neither GNAS nor KRAS mutations were asso-
ciated with expressions of phosphorylated substrates of PKA (p 5
0.113 for GNAS and p 5 0.339 for KRAS by ANOVA).
Clinicopathological relevance of molecular alterations. To
understand the clinical significance of mutations in GNAS and
KRAS and expression of Gsa and the phosphorylated substrates of
PKA in patients with IPMN, we compared these molecular pheno-
types and clinicopathological features in our cohort. Mutations in
GNAS, KRAS, or both genes did not appear to be associated with
Table 2 | Molecular phenotypes of IPMN and PDA
IPMN PDA P
Total 118 32
GNAS Wild 70 32 6.583 10
27*
Mutant 48 0
KRAS Wild 62 7 0.0016*
Mutant 56 25
Gsa Low 1 13 , 0.001
{
Moderate 34 18
High 83 1
Phosphorylated
substrates of PKA
Low 26 9 0.425
{
Moderate 56 15
High 36 8
*P values of Fisher’s exact test.
{P values of ANOVA. Gsa, G-protine alpha subunit; IPMN, intraductal papillary mucinous
neoplasm; PDA, pancreatic ductal adenocarcinoma; PKA, protein kinase A.
Figure 2 | Expression of the G-protein a subunit (B, E) and phosphorylated substrates of protein kinase A (C, F) in intraductal papillary mucinous
neoplasm(A–C)andductaladenocarcinomaofthepancreas(D–F).Diaminobenzidinewasusedasthechromogentovisualizetheimmunoreactionin
immunohistochemistry (B, C, E, F). Panels (A) and (D) show images of hematoxylin-eosin staining. Original magnification, 3200.
www.nature.com/scientificreports
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morphologic variation, macroscopic type, mural nodule, grade, or
stage (Table 3). Most IPMNs showed strong expression of Gsa
and no obvious association with the clinicopathological features
(Table 3). In contrast, the expression of phosphorylated substrates
of PKA was associated with tumor grade, being more obvious in
high-grade and invasive IPMN cases than in low-grade IPMN
cases (p 5 0.010; ANOVA) (Table 3). In survival analysis, neither
the gene mutations, each alone or in combination of GNAS and
KRAS, nor the molecular expression showed any statistically
significant associations with prognosis of patients in our cohort or
those in any subcohorts including those by morphologic type, tumor
grades, macroscopic type, or stages, although survival curves
between patients with low expression of phosphorylated PKA sub-
strates and those with moderate or high expression of the substrates
appeared different (Fig. 3).
Discussion
Using whole-exome sequencing, we identified a number of somati-
cally mutated genes that were previously unidentified in IPMN. We
further examined mutations in GNAS in archival cases of IPMN
and found that GNAS mutations occurred very frequently in this
neoplasm. On the other hand, no GNAS mutations were found in
any of the examined cases of PDA. Gsa and phosphorylated sub-
strates of PKA were evidently expressed in IPMNs, and the latter
was associated with the pathological grade of the neoplasm. These
resultsindicatethatmutationsinGNASarecommonandspecificfor
IPMN, and activation of G-protein signaling seems to contribute to
development and progression of IPMN.
Whole-exome sequencing hasrecentlyemergedasapowerfultool
toidentifyunknowncancer-associatedgenes.Usingnext-generation
sequencing technology employing a massively parallel deep sequen-
cer, it is truly affordable for individual researchers like us to perform
whole-exome sequencing ina single laboratory. A key issue fornext-
generation sequencing is data processing. Because of the short
sequencing reads, data from next-generation sequencing must be
mapped on a reference sequence. This mapping task is quite chal-
lenging because of the complexity of the human genome, which
contains numerous redundant sequences. Therefore, a significant
number of errors occur in the mapped sequencing data. In this cur-
rentstudy, wedeveloped astepwisemethodof qualifying the data,as
listed in Fig. 1, and successfully identified somatic mutations. For
this, we employed values of variation reads/all reads and total num-
ber of reads/coverage. These values were useful in dismissing false
data. This qualification method is useful for the currently employed
system, using the SOLiD system and Bioscope software, but it may
also be usefully applied for the extraction of somatic mutations from
next-generation sequencing data.
In this study, most of the somatically mutated genes identified in
IPMN by whole-exome sequencing were previously unidentified as
susceptible genes in cancer. These genes, listed in Table 1, serve a
variety of functions, and some of them are demonstrated to be rarely
mutated in cancer, as discussed below, according to the catalog of
somatic mutations in human cancers (COSMIC) (http://www.
sanger.ac.uk/genetics/CGP/cosmic/)
9. Roles of these mutated genes
in cancer phenotypes are largely unknown. KCNF1 encodes a pot-
assium channel protein and is not known for any association with
cancer
10. DYNC1H1 is a large gene composed of 78 exons encod-
ing dynein 1 heavy chain comprising 4646 residues. Dynein is a
microtubule-associated ATPase and interference of its function
results in a block of spindle formation
11. DYNC1H1 is somatically
mutated in pancreatic neuroendocrine neoplasms, ovarian cancer,
and glioblastoma multiforme
12,13. PGCP encodes blood plasma glu-
tamate carboxypeptidase andhasnotbeen reported tobemutated in
cancer
14. STAB1 encodes a large transmembrane scavenger receptor
and is mutated in breast and colon cancers and glioblastoma multi-
forme
13,15,16. PTPRM encodes a type IIB receptor protein tyrosine
phosphatase involved in regulating adhesion by dephosphorylating
components of cadherin-catenin complexes
17. PTPRM is mutated in
lung and ovarian cancers and glioblastoma multiforme
13,18. PRPF8
encodes pre-mRNA splicing factor and is mutated in lung and
Table 3 | Clinicopathological features and molecular phenotypes in IPMNs
Total
GNAS
P
KRAS
P
Gsa
P
Phosphorylated
substrates of PKA
P
Wild Mutant Wild Mutant Low Mod High Low Mod High
118 70 48 62 56 1 34 83 26 56 36
Sex Male 73 41 32 0.244* 41 32 0.208* 0 23 50 0.635
{ 15 35 23 0.640
{
Female 45 29 16 21 24 1 11 33 11 21 13
Age Mean 65.1 64.7 65.7 0.639
{ 64.9 65.2 0.692
{ 76 66.1 64.6 0.280
{ 66.0 64.6 65.2 0.896
{
Morphologic
type
GAS 64 39 25 0.588* 30 34 0.056* 0 19 45 0.127
{ 19 28 17 0.164
{
INT 40 21 19 24 16 0 11 29 6 20 14
P B 963 36 1 44 162
O N C541 50 0 05 023
Macroscopic
type
Branch-duct 48 27 21 0.599* 28 20 0.521* 0 14 34 0.660
{ 14 24 10 0.107
{
Main-duct 37 21 16 17 20 0 13 24 8 13 16
Combined 33 22 11 17 16 1 7 25 4 19 10
Mural nodule Mean (mm) 5.2 4.7 5.8 0.116
{ 4.5 6.0 0.232
{ 30 6.0 4.6 0.091
{ 5.0 5.6 4.7 0.427
{
Grade Low 58 34 24 0.940* 29 29 0.320* 0 17 41 0.550
{ 20 25 13 0.010
{
High 26 15 11 17 9 0 6 20 2 13 11
Invasive 47 34 13 16 18 1 11 22 4 18 12
UICC Stage 0A 56 34 22 0.419* 28 28 0.621* 0 16 40 0.900
{ 19 24 13 0.146
{
0 2 61 51 1 1 7 9 0 6 2 0 2 1 31 1
I A 624 33 0 24 132
I B 835 44 0 35 152
I I A 752 25 0 34 142
IIB 15 11 4 8 7 1 4 10 2 7 6
*P values of Fisher’s exact test.
{P valuesof ANOVA.GAS,gastrictype; Gsa, G-proteinalpha subunit;INT,intestinal type;IPMN,intraductal papillarymucinousneoplasm;ONC,oncocytictype;PB, pancreatobiliarytype;PKA,protein
kinase A; UICC, Union for International Cancer Control.
www.nature.com/scientificreports
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19,20. RNASE3 encodes ribonuclease A3/eosinophil
cationic protein that is toxic for pathogen and host tissues
21.
RNASE3 has not been reported to be mutated in cancer. SPHKAP
encodes A-kinase anchoring protein implicated in spatial local-
ization of protein kinase A and signal transduction and is mutated
in lung and ovarian cancers
22. MLXIPL encodes a glucose-responsive
transcription factor ChREBP that is required for efficient cell prolif-
eration of tumor cells
23. MLXIPL is mutated in pan-
creatic cancer. VPS13C encodes a member of the vacuolar protein
sorting-associated 13 gene family that is a homologue of a yeast
protein involved in trafficking of membrane proteins between the
trans-Golgi network and the prevacuolar compartment
24. VPS13C is
mutated in ovarian cancer. PRCC encodes a protein associated with
pre-mRNA splicing factor and is known to comprise a fusion gene
with TFE3 observed in papillary renal cell carcinoma
25. PRCC is
mutated in glioblastoma multiforme
13. RBM10 is a member of the
RNA binding motif gene family and is identified as a susceptibility
gene in the cleft palate
26. RBM10 is mutated in breast, colon, ovary,
pancreas, and prostate cancers, although none of these are frameshift
mutations like the one we identified, but one nonsense mutation
has been reported
20,27. RNF43 encodes an E3 ubiquitin ligase that
is overexpressed in colorectal cancer
28 and mutated in ovarian can-
cer. DOCK2 encodes a member of the CDM protein family and
regulates cell motility and cytokine production through the activa-
tion of Rac in mammalian hematopoietic cells
29. DOCK2 is mutated
in ovarian and pancreatic cancers. CENPF encodes a component of
the centromere-kinetocore complex and is overexpressed in breast
cancer
30. CENPF is also mutated in colon and ovarian cancers and
glioblastoma multiforme
13,16.
Gsa encoded by GNAS forms a heterotrimer with ß and c G-
protein subunits, which then couples with a membrane-bound
receptor, GPCR. When GPCR is activated by ligand-binding, the
receptor catalyzes exchange of guanosine triphosphate (GTP) for
guanosine diphosphate (GDP) bound to Gsa, and the GTP-bound
Gsa dissociates from the receptor and the ßc subunits. The disso-
ciated Gsa proceeds to activate specific effector molecules including
adenyl cyclase, which produces cAMP that can act as a second mes-
senger
8. Increased cAMP activates PKA, and the activated PKA
phosphorylates a variety of target molecules. The activated Gsa
hydrolyzes GTP to GDP and is converted into its inactive form.
GNAS is known to be mutated in several neoplasms, mainly of the
endocrine system and rarely in non-endocrine common cancers like
those of the breast, lung, and pancreas according to COSMIC data-
base
9. Our study has shown that frequent somatic mutations in
GNAS occur in a pancreatic non-endocrine neoplasm, namely,
IPMN. Common mutations in GNAS observed in IPMN identified
by this study as well as endocrine neoplasms reported thus far in
elsewhere are R201C and R201H. These mutations are known to
cause disruption of the intrinsic hydrolytic activity of Gsa, which
results in constitutive activation of its function
31. Our findings
of frequent GNAS mutations, together with evident expression of
Gsa and phosphorylated substrates of PKA in IPMN, indicate that
G-protein signaling is activated in this neoplasm. The mutations
in GNAS were not associated with any specific clinicopathological
features of the neoplasm. GNAS mutations were observed in low-
grade tumors as well as in high-grade tumors and invasive tumors.
These results suggest that GNAS mutations may be associated more
with initiation but less with progression of the neoplasm with some
specific clinicopathological features. Instead, although the express-
ion of phosphorylated substrates of PKA was not associated directly
with mutational phenotypes of GNAS, it was associated with the
grade of IPMN, which suggests that exacerbation of PKA activity
apparently independent from GNAS mutations may be necessary
for disease progression. Regarding multifocal nature of IPMN
2,i t
may be interesting to examine molecular features in independent
lesions in the neoplasm, which was not determined in the current
study and is an important issue for further study.
Although mutations in GNAS were common in IPMN, they
were not found in PDAs. On the other hand, mutations in KRAS
were fairly common in both types of neoplasms. More interes-
tingly, a significant proportion (25%) of IPMNs showed concurrent
Figure 3 | Kaplan–Meier survival analyses of patients with intraductal
papillary mucinous neoplasms according to molecular alterations and
expression profiles.
www.nature.com/scientificreports
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involvedinthemitogen-activatedproteinkinase(MAPK)pathway
32,
whereas GNAS is involved in the GPCR pathway. These results
highlightacriticaldifferenceinmolecularoncogenesisbetweenthese
neoplasms; PDAs depend on activation of the RAS-MAPK pathway,
whereas IPMNs depend on activation of both the RAS-MAPK and
the GPCR pathways. On the other hand, expression of phosphory-
lated substrates of PKA was observed in PDAs as well. This result
suggeststhatactivationofPKAapparentlyindependentfrommutant
Gsa may play some roles in PDA. Unraveling the details concerning
thesynergisticeffectofbothpathwaysonpancreaticductaloncogen-
esis will need to be clarified by experiments employing a genetically
engineered mouse model.
The frequent and specific mutations in GNAS found in IPMN
may provide a clue to the molecular diagnosis and targeted ther-
apy of this neoplasm. The highly specific redundancy of GNAS
mutations in IPMN may allow a sensitive and specific diagnosis
of the neoplasm with exclusion of PDA. It may also help to resolve
a recent debate regarding whether the prognosis of pancreatic
cancer associated with IPMN is better than that of pancreatic
cancer alone
33. This debate is hampered by the difficulty of precise
evaluation of an association between pancreatic cancer and IPMN.
Molecular diagnosis using information on any GNAS mutation in
pancreatic cancer may help to evaluate such associations and
to enable a better prediction of patients’ prognosis. The GPCR
pathway involving PKA is already known to be a major target
of drug development, and indeed one-third of current drugs target
GPCR pathways
34. Among such drugs, BIM-46174 is a specific
drug targeting Gsa, which can suppress malignant phenotypes
of various cancer cell lines
35. These GPCR-targeting drugs might
prove useful in treating IPMN, which will be an important area for
future study.
During preparation of this manuscript, we became aware that
Wu et al. had published a report regarding GNAS mutations in
IPMN
36. They found that 66% of 132 IPMNs harbored a GNAS
mutation, 81% harbored a KRAS mutation, and slightly more than
half (51%) harbored both GNAS and KRAS mutations, whereas at
least 1 of the 2 genes was mutated in 96.2%. The frequency of these
mutations appeared to be higher than that in our cohort. This might
be due to methodological differences in the detection of mutations.
Wuetal.usedcysticfluidsamplesandtheligationassayfordetecting
mutations, which might be more sensitive than the traditionally
conventional method we employed using DNA from dissected
paraffin-embedded tissues and Sanger sequencing for analyzing
archival cases, because a low population of mutated genes could be
uncovered by their method, with allele frequencies as low as 1%
according to their data. Moreover, they observed that the prevalence
of KRAS mutations was higher in lower-grade lesions, whereas the
prevalence of GNAS mutations was somewhat higher in more
advanced lesions. These associations seem to be inconsistent with
our data showing no particular association between the mutations
and tumor grade. These differences might be due to not only the
methodological difference but also differences in features of exam-
ined cohorts. In comparisons of some of features available between
the two cohorts, the mean age of studied patients and morphologic
types of IPMN samples seemed to be different. The mean age was
65.09 years-old in ours while 69.73 years-old in Wu’s (P , 0.001 by
ANOVA). In Wu’s study, morphological types were available for 72
samples and they were consisted of 72% of gastric type-IPMNs, 18%
of intestinal type-IPMNs, 10% of pancreatobiliary type-IPMNs, and
no oncocytic type-IPMN, which was different from the distribution
of ours (P 5 0.022 by Chi-square test). On the other hand, mac-
roscopictypes, tumorgrades,andsexdistribution didnotseemtobe
different. Besides these features, ethnic background of studied popu-
lations might be different. Resolving of these inconsistencies will be
an important issue of future study.
Methods
Tissues.Afrozentissuesampleofintraductalpapillarymucinousneoplasm,obtained
during surgery at the Tokyo Women’s Medical University Hospital, was used for
whole-exome sequencing. The patient analyzed provided written consent for use of
tissues and clinical information for research involving whole-genome sequencing.
Formalin-fixed, paraffin-embedded tissues of archival cases of 118 IPMNs and 32
PDAs of the pancreas operated upon at the Tokyo Women’s Medical University
Hospital were used for additional analysis of somatic mutations of specific genes and
forimmunohistochemistry.Clinicopathologicalfeaturesofthe patients werelistedin
Table 3 and Supplementary Table 1. These studied IPMN patients were 73 men and
45 women with the mean age of 65.1 years-old. The IPMN tissues were of 64 gastric
types, 40 intestinal types, 9 pancreatobiliary types, and 5 oncocytic types in
morphological types; 48 branch-duct types, 37 main-duct types, and 33 mixed types
in macroscopic types; 58 low-grade tumors, 26 high-grade tumors, and 47 invasive
tumors in grade of tumors; and 56 of stage 0A indicating low-grade tumors, 26 of
stage 0, 6 of stage IA, 8 of stage IB, 7 of stage IIA, and 15 of stage IIB according to the
Union for International Cancer Control staging system, which were determined as
described previously
7. Invasive IPMNs were determined as invasive carcinomas
derived from IPMN according to criteria published in elsewhere
33. This study was
approved by the Ethical Committee of the Tokyo Women’s Medical University.
Whole-exome sequencing. Methanol-fixed, hematoxylin-stained frozen sections
were prepared from the frozen tissue. Tumor cells were microdissected from each
section using a PALM Microbeam system (Carl Zeiss MicroImaging GmbH, Jena,
Germany). Genomic DNAextractionfrom collected tissues wascarriedoutusing the
ChargeSwitchH gDNA Mini Tissue kit (Life Technologies, Carlsbad, CA). The
extracted DNA was used for construction of a library using a SOLiD Fragment
Library Construction Kit (Life Technologies). The library DNA was subjected to
whole-exome enrichment using a Sureselect Human All Exon Kit (Agilent
Technologies Inc., Santa Clara, CA). The enriched library DNA was then sequenced
using the SOLiD System, a deep sequencer employing the massively parallel
sequencing method, and analyzed using Bioscope software (Life Technologies).
Sequence data were mapped on Human Genome Reference, GRCh37/hg19 (The
Genome Reference Consortium; http://www.ncbi.nlm.nih.gov/projects/genome/
assembly/grc/index.shtml). All procedures were performed according to the
manufacturers’ instructions.
Sanger sequencing. For validation of the whole-exome sequencing data, DNA was
amplified by polymerase chain reaction (PCR) using the primers listed in
SupplementaryTableS2onlineandAccuPrimePCRsystem(LifeTechnologies).The
amplified products were treated with ExoSAP-IT (GE Healthcare, Chalfont St Giles,
Buckinghamshire,UK)andsequencedusingBigdyeTerminatoranda3130xlGenetic
Analyzer (Life Technologies). For examination of mutations in GNAS and KRAS in
archival cases of IPMNs and PDAs, tumor tissues were manually dissected from
sections of formalin-fixed and paraffin-embedded tissues. Genomic DNA was
extracted using the ChargeSwitchH gDNA Mini Tissue kit (Life Technologies).
Portions of exons8 and 9 of GNAS and exons 2,3, and 4 of KRAS were amplified and
sequenced as described above using the primers listed in the Supplementary Table 2.
Immunohistochemistry. Indirect immunohistochemical staining of paraffin-
embedded tissues using the streptavidin and biotin system was performed by using
Histofine SAB-PO kit (Nichirei Biosciences Inc., Tokyo, Japan) as described
previously
37. The antibodies employed included a rabbit polyclonal anti-GNAS
(LifeSpan Biosciences, Inc., Seattle, WA) and a rabbit polyclonal anti-Phospho-(Ser/
Thr)PKASubstrate(CellSignalingTechnology,Beverly,MA).Tocheckspecificityof
staining, a negative control staining without specific primary antibody was carried
out. Immunohistochemical results were evaluated as follows: The intensity score (IS)
wasevaluatedbycomparingstainingintumorandisletsofLangerhansandgradedas
0 for no staining (completely negative or extremely faint similar to non-specific
staining of surrounding stromal tissue), 1 for evident staining (definitely positive but
weakerthanthatinisletsofLangerhans),and2forstrongstaining(denselypositiveas
thatin islets of Langerhans). The proportional score (PS) wasgraded as 0 forstaining
in ,5% of the area, 1 for staining in $5% but , 30% of the area, 2 for staining in $
30%but,70%ofthearea,and3forstainingin$70%ofthearea.Thefinalscore(FS)
was calculated and graded as follows: low (FS 1), IS3 PS 5 0 and 1; moderate (FS 2),
IS3PS52and3;andhigh(FS3),IS3PS54and6.ThescoringwasmadebyY.K.
andT.F.independently.Theconcordanceratiowas.95%ineachcase.Differencesin
opinion were resolved by re-evaluating the sections and by reaching a consensus.
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